Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: DrugBank:EXPT01586 (
G418
)
2,237
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The effects of RNAi-mediated gene silencing of LRlG1 on proliferation and invasion of the human glioma cell line U251-MG and the possible mechanisms were explored in this study. The plasmids pGenesil2-
LRIG1
-shRNA1 and pGenesil2-
LRIG1
-shRNA2 were transfected into U251-MG glioma cells respectively by using Lipofectamine 2000 and the transfected cells in which the
LRIG1
expression was stably suppressed were selected by
G418
. The cells transfected with negative shRNA served as control. The expression levels of
LRIG1
mRNA and protein were measured by qRT-PCR and Western blotting, respectively. The cell cycle was analyzed by flow cytometry. The results showed that
LRIG1
mRNA expression was reduced by 70% and 58% and LRIG1 protein expression by 58% and 26% in U251-MG cells transfected with pGenesil2-
LRIG1
-shRNAl and pGenesil2-
LRIG1
-shRNA2 relative to the negative shRNA-transfected U251-MG cells. The proliferative capacity of the
LRIG1
specific siRNA-transfected cells was stronger than that of control cells. Cell cycle analysis showed that silencing
LRIG1
significantly increased the percentage of S phase cells and the proliferation index (P<0.01). Moreover, silencing
LRIG1
could promote the invasion of U251-MG cells (P<0.05). These findings suggested that
LRIG1
-targeting siRNA can exert a dramatically inhibitory effect on RNA transcription and protein expression of
LRIG1
, and
LRIG1
down-regulation could promote the proliferation of U251-MG cells, arrest U251-MG cells in S phase, and enhance the invasion of U251-MG cells.
...
PMID:Effects of RNAi-mediated gene silencing of LRIG1 on proliferation and invasion of glioma cells. 2252 25